Legend Biotech Corporation

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-02-12 EST			5-day change	1st Jan Change
18.06 ^USD	-2.59%		+8.14%	-16.93%

02-06	Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026	CI
01-23	Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026	CI

Legend Biotech Said to Consider Second Listing Outside US

Published on 09/05/2025 at 10:52 am EDT

MT Newswires

Latest news about Legend Biotech Corporation

02-06	Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026	CI
01-23	Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026	CI
01-22	TD Cowen Downgrades Legend Biotech to Hold From Buy, Adjusts Price Target to $21 From $62	MT
01-21	Genscript Biotech Associate Books $555 Million in Q4 CARVYKTI Sales	MT
01-14	Legend Biotech Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:00 AM
01-12	Legend Biotech highlights recent business updates at 44th annual J.P. Morgan Healthcare conference	RE
01-08	RBC Cuts Price Target on Legend Biotech to $66 From $74, Keeps Outperform Rating	MT
01-07	Oppenheimer Initiates Legend Biotech at Outperform With $75 Price Target	MT
01-05	Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT
12-08	Legend Biotech Corporation Highlights New CARVYKTI Data in Multiple Myeloma and First-In-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma	CI
12-06	Legend Biotech highlights new Carvykti® data in multiple myeloma and first-in-human results from novel CAR-T platform in non-Hodgkin lymphoma at ASH 2025	RE
11-13	Legend Biotech Corporation Celebrates Official Opening of New Cell Therapy Research and Development Facility in Philadelphia	CI
11-13	RBC Trims Price Target on Legend Biotech to $74 From $75, Keeps Outperform Rating	MT
11-13	Truist Lowers Price Target on Legend Biotech to $70 From $71, Keeps Buy Rating	MT
11-12	Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	Legend Biotech Corporation, Q3 2025 Earnings Call, Nov 12, 2025
11-12	Legend Biotech Q3 Adjusted Loss Narrows, Revenue Rises	MT
11-12	Legend Biotech Q3 revenue slightly misses estimates	RE
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q3 Revenue $272.3M, vs. FactSet Est of $274.4M	MT
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q3 Adjusted Loss $0.05 per Share	MT
25-10-14	GenScript Associate Books $524 Million in Q3 CARVYKTI Sales	MT
25-10-14	Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025	CI
25-10-14	Legend Biotech Corporation Announces U.S. Fda Approves Label Updates for Carvykti® Car-T Cell Therapy to Include Overall Survival Data	CI

Chart Legend Biotech Corporation

Duration

Period

LEGN: Dynamic Chart

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,900

Sector

Biotechnology & Medical Research

Calendar

03-17 - Q4 2025 Earnings Release (Projected)

More about the company